Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of borderline changes in 3‑month protocol kidney graft biopsy with methylprednisolone
2006-000607-42Phase 4Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Feb 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of methylprednisolone in kidney allograft rejection and Kidney allograft dysfunction, sponsored by Institute for Clinical and Experimental Medicine. Primary endpoints: Graft function at 1 year post‑transplant and Graft function at 2 years post‑transplant. Started Feb 2006; status: completed.
02
Drugs
methylprednisolone
03
Conditions
kidney allograft rejectionKidney allograft dysfunction
Beyond the preview
Go deeper on 2006-000607-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000607-42.